NAOV - NanoVibronix, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
3.0100
-0.0100 (-0.33%)
At close: 12:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.0200
Open3.0100
Bid0.0000 x 800
Ask0.0000 x 900
Day's Range3.0100 - 3.0424
52 Week Range2.5000 - 4.9800
Volume451
Avg. Volume6,366
Market Cap12.386M
Beta (3Y Monthly)-0.73
PE Ratio (TTM)N/A
EPS (TTM)-0.8880
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.50
Trade prices are not sourced from all markets
  • GlobeNewswire25 days ago

    NanoVibronix Announces Closing of $3.2 Million Private Placement

    NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® surface acoustic wave (SAW) device, which utilizes the Company’s proprietary and patented low intensity, SAW ultrasound technology, today announced that it closed a private placement transaction in which it issued and sold to existing stockholders 1.6 million Series E convertible preferred stock and 1.6 million 7-year warrants to purchase Series E convertible preferred stock at a price of $2.50 per share for gross proceeds to the Company of $3.2 million. The Series E convertible preferred shares are convertible into shares of common stock on a one-for-one basis. The Company plans to submit to stockholders for approval, within 90 days of the closing of the private placement, the issuance of the shares of common stock issuable upon conversion of the Series E preferred stock, in accordance with the rules of the Nasdaq Stock Market.

  • ACCESSWIRElast month

    NanoVibronix Announces Presentation of PainShield(R) to HCPCS Workgroup at CMS

    ELMSFORD, NY / ACCESSWIRE / June 19, 2019 / NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® surface acoustic wave (SAW) device, which utilizes the Company's proprietary and patented low intensity, SAW ultrasound technology, announces that on June 12, 2019, the Company had the opportunity to present their signature product, PainShield® surface acoustic wave device, to the Healthcare Common Procedure Coding System (HCPCS) Workgroup at the Centers for Medicare & Medicaid Services (CMS) offices in Baltimore, Maryland. The HCPCS Workgroup is tasked with evaluating products, supplies, and services that are not included in the Current Procedural Terminology (CPT) codes, such as ambulance services and durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) when used outside a physician's office, as well as recommending appropriate payment by the Medicare and Medicaid payment systems.

  • ACCESSWIRElast month

    NanoVibronix Announces Rescheduling of Annual Meeting of Stockholders

    ELMSFORD, NY / ACCESSWIRE / June 14, 2019 / NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® surface acoustic wave (SAW) device, which utilizes the Company's proprietary and patented low intensity, SAW ultrasound technology, announces that the Company's 2019 Annual Meeting of Stockholders, originally scheduled for 10:00 a.m. Eastern Time yesterday, June 13, 2019, was adjourned due to the lack of the requisite quorum. During the period of the adjournment, the Company will continue to solicit proxies from its stockholders with respect to the proposals set forth in the Company's proxy statement. The Company encourages all stockholders who have not yet voted to do so before June 19, 2019 at 11.59 p.m. Eastern time.

  • Benzingalast month

    NanoVibronix Announces Planned Launch Of CBD Patch, Cream

    Nanocap medical device company NanoVibronix (NASDAQ: NAOV ) announced it's developing cannabidiol patches and cream utilizing a proprietary and nanoparticle-based infusion process. CBD is one of the naturally ...

  • GlobeNewswirelast month

    NanoVibronix Announces Planned Launch of CBD Patch and Cream for PainShield® Designed to Amplify Therapeutic Effect

    ELMSFORD, N.Y., June 05, 2019 (GLOBE NEWSWIRE) --  NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® surface acoustic wave (SAW) device, which utilizes the Company’s proprietary and patented low intensity, SAW ultrasound technology, today announced that it is developing a cannabidiol (CBD) patch and cream utilizing a proprietary and nanoparticle-based infusion process.  NanoVibronix intends to make the CBD patch as well as similarly formulated CBD cream available in combination with PainShield® as PainShield CBD™. NanoVibronix intends to demonstrate that coupling the infused patch and cream with PainShield® will increase absorption and may provide sustained pain relief for up to 24 hours.  The Company believes that this will be the first known ultrasound-based pain relief product available in combination with CBD, which can be used at home, and outside of a clinical setting, as an opioid-alternative.

  • Zacks Small Cap Researchlast month

    NAOV: Several Major Milestones Expected This Year Including FDA Filings for OTC PainShield, UroShield

    NanoVibronix (NAOV) filed their 10-Q for Q1 2019 ending March 31st and released a corresponding business update. OTC approval, if and when achieved, would be a major milestone as it would allow for purchase and use of PainShield without the need for a doctor’s prescription – which has been a major impediment to sales to-date.

  • ACCESSWIRE2 months ago

    NanoVibronix Announces Planned Launch of CBD Patch and Cream for PainShield(R) Designed to Amplify Therapeutic Effect

    ELMSFORD, NY / ACCESSWIRE / June 3, 2019 / NanoVibronix, Inc., (NAOV), a medical device company that produces the PainShield® surface acoustic wave (SAW) device, which utilizes the Company's proprietary and patented low intensity, SAW ultrasound technology, today announced that it is developing a cannabidiol (CBD) patch and cream utilizing a proprietary and nanoparticle-based infusion process. NanoVibronix intends to demonstrate that coupling the infused patch and cream with PainShield® will increase absorption and may provide sustained pain relief for up to 24 hours. The Company believes that this will be the first known ultrasound-based pain relief product available in combination with CBD, which can be used at home, and outside of a clinical setting, as an opioid-alternative.

  • ACCESSWIRE2 months ago

    NanoVibronix Provides Business Update for the First Quarter of 2019

    ELMSFORD, NY / ACCESSWIRE / May 24, 2019 / NanoVibronix, Inc., (NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today provided a business update for the first quarter ended March 31, 2019.

  • Zacks Small Cap Research3 months ago

    NAOV: Foundation Built in 2018, Expected to Catalyze Growth Beginning Later This Year

    Each day they completed a Visual Analog Scale (indicating pain severity) and medication logs (reporting how much pain medication they took). In addition, while control saw a 1.5% decrease in breakthrough pain medication use (including opioids), PainShield patients used 46.4% less. The improvements in VAS scores as well as in the amount of pain medications used (both favoring PainShield) were statistically significant (charts below).

  • ACCESSWIRE4 months ago

    NanoVibronix Provides Year-End Business Update

    ELMSFORD, NY / ACCESSWIRE / April 2, 2019 / NanoVibronix, Inc., (NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today provided a business update for the year-ended December 31, 2018. "2018 was a transformational year for the Company, as we laid the foundation for anticipated growth in latter part of 2019 and beyond," said Brian Murphy, CEO of NanoVibronix. "Specifically, we completed a number of important trials, which we believe will be important for expanded regulatory approvals and validation for distributors, as well as potential partners.

  • ACCESSWIRE4 months ago

    NanoVibronix Announces Reimbursement Approvals for PainShield(R) in the U.S.

    ELMSFORD, NY / ACCESSWIRE / March 25, 2019 / NanoVibronix, Inc., (NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that it has begun receiving reimbursement approvals for PainShield® in the United States-market through commercial and workman's compensation companies, in connection with American Health Insurance Plans (AHIP) and Centers for Medicare & Medicaid Services (CMS) programs designed to combat the opioid epidemic. "AHIP is the largest and most active national association for healthcare coverage companies and CMS controls nearly all government healthcare payments," said Brian Murphy, CEO of NanoVibronix.

  • ACCESSWIRE4 months ago

    NanoVibronix Announces Exclusive Agreement for Distribution of PainShield(R) and UroShield(R) in Italy

    ELMSFORD, NY / ACCESSWIRE / March 20, 2019 / NanoVibronix, Inc., (NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced it has entered into an exclusive agreement with N.B.A. medica s.r.l.

  • ACCESSWIRE4 months ago

    NanoVibronix CEO to Present UroShield(R) at the U.S. National Institutes of Health's Catheter-Associated Urinary Tract Infections Technology Workshop

    ELMSFORD, NY / ACCESSWIRE / March 8, 2019 / NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company utilizing its proprietary and patented low intensity surface acoustic wave (SAW) technology, today ...

  • ACCESSWIRE4 months ago

    NanoVibronix Reports Positive Interim Tennis Elbow Study Results Using PainShield(R)

    ELMSFORD, NY / ACCESSWIRE / March 7, 2019 / NanoVibronix, Inc, (NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced results of a study entitled, "The Effects of the NanoVibronix's PainShield® Surface Acoustic Waves on the Symptoms of Lateral Epicondylitis." The clinical study was conducted by Dr. David Lemak, a leading orthopedic surgeon with Birmingham Orthopedic and Sports Specialists. The trial was a randomized, double blinded study for 30 days that evaluated the effectiveness and safety of PainShield™ Surface Acoustic Wave (SAW) technology on patients suffering from pain and discomfort, as well as limited mobility caused by the effects of chronic or acute lateral epicondylitis (LE) ("tennis elbow").

  • ACCESSWIRE5 months ago

    NanoVibronix Launches New Consumer and Industry Focused Website Highlighting Advantages of PainShield, UroShield and WoundShield

    ELMSFORD, NY / ACCESSWIRE / February 4, 2019 / NanoVibronix, Inc, (NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced it has launched a new website (www.nanovibronix.com) designed to highlight the advantages of the Company's proprietary and patented low intensity surface acoustic wave (SAW) devices, including PainShield®, UroShield® and WoundShield®. The new site includes a detailed overview of the products, which employ small, disposable transducers that transmit low frequency, low intensity ultrasound acoustic waves.

  • GlobeNewswire5 months ago

    NanoVibronix Announces Publication of PainShield™ Trigeminal Neuralgia Study in the Journal of Anesthesiology and Pain Research

    NanoVibronix, Inc., (NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced the publication of an independent study entitled, “The Effect of a Surface Acoustic Wave (SAW) Device on the Symptomatology of Trigeminal Neuralgia,” which was published in the January 2019 issue of Journal of Anesthesiology and Pain Research, a leading peer-reviewed journal in the field of anesthesiology. The study publication is available at: https://www.omicsonline.org/open-access/the-effect-of-surface-acoustic-wave-saw-device-on-the-of-trigeminal-neuralgia.pdf.

  • Zacks Small Cap Research6 months ago

    NAOV: Zacks SCR Initiates Coverage of NanoVibronix

    Zacks SCR Senior Med-Tech analyst and Director of Research Brian Marckx, CFA has initiated coverage of NanoVibronix, Inc. with a $9.00/share price target. NanoVibronix, Inc. (NAOV), develops, manufactures and commercializes proprietary low intensity low frequency wearable ultrasound medical devices for the treatment of pain, reduction in bacterial colonization and biofilm disruption, and for wound healing. The relative safety of low intensity, low frequency ultrasound and compact size and simple operation of NAOV’s technology lend themselves to at-home use.

  • GlobeNewswire6 months ago

    NanoVibronix Enters Collaboration Agreement with Fritz Clinic to Offer PainShield® as an Alternative to Opioids for Pain Management

    NanoVibronix, Inc, (NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that it has entered into a collaboration agreement with the Fritz Clinic, which operates 7 locations in North America dedicated to wellness, longevity, and preventative medicine, including comprehensive services related to opiate dependency and drug detox. Fritz Clinic intends to offer its patients NanoVibronix’s PainShield® as an alternative treatment option for pain, and to aid in decreasing the dependency on opioids for pain relief. Dr. Lyman “Woodie” Fritz, founder of the Fritz Clinic, stated, “For the past 15 years, our practice has focused on providing health and wellness protocols to enhance longevity and quality of life.

  • GlobeNewswire7 months ago

    NanoVibronix Announces Expanded Agreement with MDS Pharm Ltd. to Include Distribution of UroShield® in Israel

    NanoVibronix, Inc., (NAOV), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced it has expanded its distribution agreement with MDS. MDS Pharm Ltd. is a leading distributor of medical equipment for home-care and self-diagnostics. MDS has an established distribution network in Israel that includes health insurance providers, private pharmacies, health stores, beautician centers, private clinics, and leading health websites.

  • GlobeNewswire7 months ago

    NanoVibronix Signs Major Distributor in India for UroShield®

    NanoVibronix, Inc, (NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced, in partnership with Morulaa HealthTech, NanoVibronix’s marketing partner in India, that they signed a new distribution agreement for UroShield® with Cnergy Group of Companies.  Cnergy is one of the leading medical device distributors in India, headquartered in Chennai, Tamilnadu, with over 100 employees. UroShield™ is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm on indwelling urinary catheters and increase antibiotic efficacy, ultimately reducing the incidence of catheter-associated urinary tract infections (CAUTI).

  • GlobeNewswire7 months ago

    NanoVibronix Signs with Exclusive Distributor in Switzerland for UroShield®

    NanoVibronix, Inc, (NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced it has signed a new distribution agreement for UroShield® with Stöckli Medical AG (Stockli), a Swiss medical device company headquartered in Oberkirch that distributes specialized clinical devices throughout Switzerland, focusing on innovative products. UroShield® is a small external medical device that has been developed to prevent bacterial colonization and biofilm formation on both urethral and suprapubic catheters by means of the low frequency/low intensity ultrasonic waves that it generates.

  • GlobeNewswire7 months ago

    NanoVibronix Announces Selection of Leading International Contract Manufacturer to Support Rapid Scale-up, Lower Price Points and Enhance Profitability

    NanoVibronix, Inc, (NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced it has appointed Quasar as its contract manufacturer for the PainShield®, UroShield®, WoundShield® as well as other devices. Quasar (http://www.quasar-med.com/) is a medical device manufacturer with over 30 years of experience, serving major brands worldwide, with complex catheters, disposables, and FDA regulated assemblies. Quasar delivers a full lifecycle array of engineering services, including design-to-cost, jigs and tool design, as well as unique production process-design services that allow for the highest levels of efficiency and productivity.

  • GlobeNewswire7 months ago

    NanoVibronix Announces Publication of Study Measuring the Effect of Surface Acoustic Waves on Bacterial Load and Preventing Catheter-Associated Urinary Tract Infections

    NanoVibronix, Inc, (NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced the publication of an independent study, entitled “The Effect of Surface Acoustic Waves on Bacterial Load and Preventing Catheter-Associated Urinary Tract Infections (CAUTI) in Long Term Indwelling Catheters,” which was published in the December 2018 issue of Medical & Surgical Urology, a leading peer-reviewed journal in the field of urology.

  • GlobeNewswire8 months ago

    New Research: Key Drivers of Growth for Nanovibronix, Griffin Industrial Realty, Iteris, NAPCO Security Technologies, Nortech, and New Age Beverage — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire8 months ago

    NanoVibronix Provides Business Update for the Third Quarter of 2018

    NanoVibronix, Inc, (NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today provided a business update for the third quarter ended September 30, 2018. Brian Murphy, Chief Executive Officer of NanoVibronix, commented, "When I first joined NanoVibronix as CEO, the Company had developed a potentially breakthrough technology, but lacked the key ingredients for success.  The past 12 months have been transformational for the Company, as we have laid the foundation for our commercial launch in each of the key verticals.  First, we completed a number of important trials that will be important for expanded regulatory approvals and validation for distributors as well as potential partners.  We have a number of additional trials planned that we expect to complete near-term.  Additionally, we have put in place the commercial infrastructure necessary to support an aggressive launch.